Informação do artigo
O texto completo está disponível em PDF
Referências
[1]
R.T. Stein, D. Sherrill, W.J. Morgan, C.J. Holberg, M. Halonen, L.M. Taussig, et al.
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.
Lancet., 354 (1999), pp. 541-545
[2]
D.K. Shay, R.C. Holman, R.D. Newman, L.L. Liu, J.W. Stout, L.J. Anderson.
Bronchiolitis-associated hospitalizations among US children, 1980-1996.
JAMA., 282 (1999), pp. 1440-1446
[3]
L.J. Stockman, A.T. Curns, L.J. Anderson, G. Fischer-Langley.
Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
Pediatr Infect Dis J., 31 (2012), pp. 5-9
[4]
H. Nair, D.J. Nokes, B.D. Gessner, M. Dherani, S.A. Madhi, R.J. Singleton, et al.
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
Lancet., 375 (2010), pp. 1545-1555
[5]
C.B. Hall, G.A. Weinberg, M.K. Iwane, A.K. Blumkin, K.M. Edwards, M.A. Staat, et al.
The burden of respiratory syncytial virus infection in young children.
N Engl J Med., 360 (2009), pp. 588-598
[6]
E.A. Simoes.
Respiratory syncytial virus infection.
Lancet., 354 (1999), pp. 847-852
[7]
E.E. Wang, B.J. Law, D. Stephens.
Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.
J Pediatr., 126 (1995), pp. 212-219
[8]
K. Kristensen, T. Hjuler, H. Ravn, E.A. Simões, L.G. Stensballe.
Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.
Clin Infect Dis., 54 (2012), pp. 810-817
[9]
C.G. García, R. Bhore, A. Soriano-Fallas, M. Trost, R. Chason, O. Ramilo, et al.
Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.
Pediatrics., 126 (2010), pp. e1453-e1460
[10]
C.B. Hall, G.A. Weinberg, A.K. Blumkin, K.M. Edwards, M.A. Staat, A.F. Schultz, et al.
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.
Pediatrics., 132 (2013), pp. e341-e348
[11]
S. Yusuf, G. Piedimonte, A. Auais, G. Demmler, S. Krishnan, P. Van Caeseele, et al.
The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus.
Epidemiol Infect., 135 (2007), pp. 1077-1090
[12]
B. Paes, C. Craig, W. Pigott, A. Latchman.
Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data.
Pediatr Infect Dis J., 32 (2013), pp. e360-e364
[13]
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102:531-7.
[14]
T.F. Feltes, A.K. Cabalka, H.C. Meissner, F.M. Piazza, D.A. Carlin, F.H. Top Jr., et al.
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
J Pediatr., 143 (2003), pp. 532-540
[15]
X. Carbonell-Estrany, E.A. Simões, R. Dagan, C.B. Hall, B. Harris, M. Hultquist, et al.
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Pediatrics., 125 (2010), pp. e35-e51
[16]
M.O. Blanken, M.M. Rovers, J.M. Molenaar, P.L. Winkler-Seinstra, A. Meijer, J.L. Kimpen, et al.
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
N Engl J Med., 368 (2013), pp. 1791-1799
[17]
V.I. Bedoya, V. Abad, H. Trujillo.
Frequency of respiratory syncytial virus in hospitalized infants with lower acute respiratory tract infection in Colombia.
Pediatr Infect Dis J., 15 (1996), pp. 1123-1124
[18]
J.G. Piñeros, H. Baquero, J. Bastidas, J. García, O. Ovalle, C.M. Patiño, et al.
Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia.
J Pediatr (Rio J)., 89 (2013), pp. 544-548
[19]
P. Lehtinen, A. Ruohola, T. Vanto, T. Vuorinen, O. Ruuskanen, T. Jartti.
Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema.
J Allergy Clin Immunol., 119 (2007), pp. 570-575
[20]
B.L. Bennett, R.P. Garofalo, S.G. Cron, Y.M. Hosakote, R.L. Atmar, C.G. Macias, et al.
Immunopathogenesis of respiratory syncytial virus bronchiolitis.
J Infect Dis., 195 (2007), pp. 1532-1540
[21]
C. García, A. Soriano-Fallas, J. Lozano, N. Leos, A.M. Gomez, O. Ramilo, et al.
Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhinovirus bronchiolitis.
Pediatr Infect Dis J., 31 (2012), pp. 86-89
[22]
C.L. Larrañaga, S.L. Ampuero, V.F. Luchsinger, F.A. Carrión, N.V. Aguilar, P.R. Morales, et al.
Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus.
Pediatr Infect Dis J., 28 (2009), pp. 867-873
[23]
C. Mella, M.C. Suarez-Arrabal, S. Lopez, J. Stephens, S. Fernandez, M.W. Hall, et al.
Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis.
J Infect Dis., 207 (2013), pp. 564-573
Ferramentas
Publicar em
Jornal de Pediatria
Edição nº 1
Faça o download da edição nº1 do Jornal de Pediatria, de 1934
Ano
1934
Jornal do Pediatria nº1
